Chronic treatment with FK506 increases p70 S6 kinase activity associated with reduced nitric oxide synthase activity in rabbit hearts

Cardiovascular Drugs and Therapy

Volumn 14, Issue 3, 2000, Pages 329-336

  Minamino, Tetsuo ^a   Kitakaze, Masafumi ^a   Ueda, Yasunori ^a   Asanuma, Hiroshi ^a   Papst, Philip J ^b   Kuzuya, Tsunehiko ^a   Terada, Naohiro ^b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

FK506; Hypertrophy; Nitric oxide synthase; p70 S6 kinase

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE SYNTHASE; S6 KINASE; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; HEART; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; RABBITS; RIBOSOMAL PROTEIN S6 KINASES; TACROLIMUS; VASODILATION;

EID: 0033934836     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007890827297     Document Type: Article

References (40)

1. 1. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. I. Fermention, isolation, and physico-chemical and biological characteristics. J Antibiot 1987;40:1249-1255.
2. 2. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
3. 3. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-983.
4. 4. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996;111:764-772.
5. 5. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341:755-757.
6. 6. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-141.
7. 7. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phophorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 1993;90:9808-9812.
8. 8. Nagashima H, Yajima T, Quertermous T, Kawana M. Immunosuppresant FK506 enhances phosphorylation of nitric oxide synthase in endothelial cells (abstr). Circulation 1995;1-365.
9. 9. Sabatinie DM, Lai MM, Synder SH. Neural roles of immunophilins and their ligands. Mol Neurobiol 1997;15:223-239.
10. 10. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-975.
11. 11. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-896.
12. 12. Chang RK, Alzona M, Alejos J, Jue K, McDiarmid SV. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol 1998;81:1277-1280.
13. 13. Schwitter J, De Marco T, Globits S, et al. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: Possible interaction with cyclosporine medication. J Heart Lung Transplant 1999;18:1003-1013.
14. 14. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990;66:1561-1575.
15. 15. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
16. 16. Kolpakow V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995;76:305-309.
17. 17. Uttam CG, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
18. 18. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-818.
19. 19. Ritchie RH, Schiebinger RJ, Lapointe MC, Marsh JD. Angiotensin II-mediated hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide (abstr). Circulation 1997;96:1-551.
20. 20. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 1992;90:647-652.
21. 21. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-287.
22. 22. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Circ Res 1995;77:1040-1052.
23. 23. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits α1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 1997;81,176-186.
24. 24. Pround CG. p70 S6 kinase: An enigma with variations. Trends Biochem Sci 1996;21:181-185.
25. 25. Chou MM, Blenis J. The 70 kDa S6 kinase: Regulation of a kinase with multiple roles in mitogenic signaling. Curr Opin Cell Biol 1995;7:806-814.
26. 26. Stewart MJ, Thomas G. Mitogenesis and protein synthesis: A role for ribosomal protein S6 phosphorylation? Bioeassay 1994;16:809-815.
27. 27. Minamino T, Terada N, Papst PJ, et al. Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy through activation of p70 S6 kinase (abstr). Circulation 1998;98:1-550.
28. 28. Terada N, Franklin RA, Lucas JJ, Blenis J, Gelfand EW. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem 1993;268:12062-12068.
29. 29. Terada N, Patel HR, Takase K, Kohno K, Nairn A, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 1994;91:11477-11481.
30. 30. Alcorta DA, Crews CM, Sweet LJ, Bankston L, Jones SW, Erikson RL. Sequence and expression of chicken and mouse rsk: Homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol 1989;9:3850-3859.
31. 31. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
32. 2+-independent nitric oxide synthases. FEBS Lett 1991;291:145-149.
33. 33. Minamino T, Kitakaze M, Sato H, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vas Biol 1997;17:3191-3195.
34. 34. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acethylcholine. Nature 1980;288:373-376.
35. 35. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997;17:1846-1858.
36. 36. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995;77:841-848.
37. 37. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993;92:99-104.
38. s6k is activated by CCK in rat pancreatic acini. Am J Physiol 1997;273:C101-C109.
39. 39. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
40. 40. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-962.